Lizard Venom has played a crucial role to help humans take a diabetes bite and obesity.
The Gila monster is a large, magnificent and poisonous reptile that lives in the desert that is found through the southwest of the United States and Mexico. A toxic bite of the GILA can cause scorching pain, loss of consciousness and in strange cases, Death.
However, a specific Element in the poison Or the dangerous Gila inspired the development of glucagon-similar peptide agonists (LPG-1) such as Ozempic and Wagovy.
GLP-1 receiver agonists are synthetic drugs that mimic GLP-1 hormone, which is naturally released in the intestine after eating. This hormone helps regulate appetite creating a feeling of fullness.
At the end of the 1990s, the Canadian endocrinologist Daniel J. Drucker, a pioneer in the treatment of diabetes whose work raided Ozempic, was looking for a hormone similar to LPG-1. He believed that in a form of slow solution, such a hormone could function as an appetite suppressor and a blood sugar regulator.
How Gila’s monsters slow down his metabolism
Drucker learned that a research team led by Dr. John Eng in the veteran administration center at Bronx, NY, had sequenced proteins in Gila’s monster poison And they found two that resemble Human LPG-1.
ENG discovered that after prolonged periods without food, the Gila monster can slow down its metabolism and maintain constant levels of blood sugar without affecting their health.
Analyzing the lizard poison, he discovered a peptide that called Excendin, which triggers the synthesis and liberation of insulin of beta cells in the pancreas.
Inspired by these findings, Drucker and his team acquired and dissected a Gila monster. His work confirmed that reptile genes produce the exendin-4 protein.
Unlike the LPG-1 that is in the human body, which remains active for only two minutes-expendin-4 remains active for hours, racing the way for the possibility that the protein can be used to treat diabetes and obesity.
Get LPG-1 to the masses
After more tests, this GLP-1 agonist was considered safe and effective and was approved by the FDA for the treatment of type 2 diabetes in 2005.
Since then, the drug has become very popular as a weight loss treatment and has been related to A series of health benefits.
However, the popularity of GLP-1 drugs has led to an explosion in counterfeit products.
Do you have Ozempic? Mark the box to see these numbers
In A April 14 advertisementThe Federal Drug Administration declared that Novo Nordisk, manufacturer of Ozempic and Wogovy, notified the agency that “several hundred Ozempic injection units (Semaglutida) falsified 1 mg” were in the drug supply chain in the United States.
FDA has advised patients, wholesalers, retail pharmacies and health professionals to review any Ozempic product in their possession.
Any medication labeled with the Lot Number PAR0362 and has a serial number that begins with the first eight digits 51746517 should not be used, sold or distributed according to the agency.
The seized products are currently being tested by the FDA and Novo Nordisk to determine the identity, quality and safety of medicines.
